<DOC>
	<DOCNO>NCT01605201</DOCNO>
	<brief_summary>The purpose study investigate safety feasibility implant engineer cartilage graft obtain culture expand autologous nasal chondrocytes within collagen type I/III membrane cartilage defect femoral condyle and/or trochlea knee traumatic injury .</brief_summary>
	<brief_title>Tissue Engineered Nasal Cartilage Regeneration Articular Cartilage</brief_title>
	<detailed_description>Articular cartilage injury prime target regenerative technique , since spontaneous heal poor untreated defect predispose osteoarthritis . Common current strategy arthroscopic debridement , microfracture , autologous osteochondral grafting , use allograft autologous chondrocytes implantation ( ACI ) still drawbacks long complex rehabilitation time , technically challenging operation technique , defect-size limitation , donor-site morbidity , limited graft material high cost . Furthermore many technique show unsatisfactory long term result due inferior quality repair tissue compare native cartilage yet prove cost versus benefit . These drawback could overcome use tissue engineer nasal cartilage graft , thereby reduce donor site morbidity without introduce additional risk complication technically challenge technique . This study phase I , prospective , uncontrolled , investigator initiate clinical trial involve 25 patient , objective demonstrate safety feasibility use engineer nasal cartilage graft repair articular cartilage . The specific surgical target trial repair one two full-thickness cartilage defect 2 cm2 8 cm2 ( per lesion , exceed total 8 cm2 lesion ) due traumatic injury femoral condyle and/or trochlea knee .</detailed_description>
	<criteria>Size defect femoral cartilage : one two symptomatic lesion ( ) grade IIIIV 2 cm2 8 cm2 femoral condyle and/or trochlea Other : Age : 1855 year Written inform consent patient Defect : Lesions small 2cm2 great 8cm2 Total area lesion big 8cm2 Lesions femoral condyle and/or trochlea Any evidence follow disease target joint : septic arthritis ; inflammatory joint disease ; gout ; recurrent episodes pseudogout ; Paget disease bone ; ochronosis ; acromegaly ; hemochromatosis ; Wilson disease ; primary osteochondromatosis ; heritable disorder ; collagen gene mutation Presence clinically relevant cartilage lesion patella ( second lesion ) Patellofemoral cartilage lesion Presence relevant complex knee injury affect bone and/or ligament Osteochondritis dissecans : recent ( within 1 year baseline ) ; depth lesion &gt; 0.5 cm ; subchondral sclerosis Advanced osteoarthritis ( defined Radiographic Atlas Osteoarthritis , grade 23 ) Varus valgus malalignment exceed 5Â° ( kiss lesion ) Medical history : gravidity ( Pregnancy ) breast feed presence multiple severe allergy ( include porcine collagen , streptomycin penicillin ) Osteoarthritis Current diagnosis osteomyelitis Any clinically significant symptomatic vascular neurologic disorder low extremities A blood result show liver enzyme ( serum glutamic oxaloacetic transaminase , serum glutamic pyruvic transaminase , alkaline phosphatase ) 2 time upper limit normal result clinical investigator 's mind clinically important Creactive protein level great 10 mg/L Uncontrolled diabetes Renal insufficiency Previous pacemaker implantation Any concomitant painful disable disease spine , hip , low limb would interfere evaluation afflict knee Mosaicplasty ( osteochondral autograft transfer system ) Microfracture perform less 1 year baseline Received hyaluronic acid intraarticular injection afflict knee within last 6 month baseline Meniscal transplant ( previous/present ) Meniscal suture meniscal arrow ipsilaterally ( present previous resorbed ) Taking specific osteoarthritis drug , chondroitin sulfate , diacerein , nglucosamine , piascledine , capsaicin , within 2 week baseline visit Corticosteroid therapy systemic intraarticular route within last month baseline intramuscular oral corticosteroid within last 2 week baseline Chronic use anticoagulant Patients human immunodeficiency virus , hepatitis , syphilis Malignancy Alcohol drug ( medication ) abuse Poor general health condition judge investigator Body mass index &gt; 35 kg/m2 Medication : chronic treatment steroid growth factor ( immunomodulatory drug ) Other : Participation concurrent clinical trial Participation previous clinical trial within 1 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Chondral lesion knee traumatic injury</keyword>
</DOC>